🧬 Aging Wiki

veins

Properties1
aliasesvenous system, venous wall, vein, veins, venules, great saphenous vein, GSV, small saphenous vein, capacitance vessels

13 min read

Veins (venous system)

The venous system is the low-pressure, high-compliance return circulation. Veins are capacitance vessels — at rest they hold roughly two-thirds of total blood volume — and are structurally distinct from arteries: thinner walls, a much smaller tunica media with less elastin and smooth muscle relative to lumen, greater distensibility, and — critically — bicuspid venous valves that enforce unidirectional flow against gravity. This page is the venous counterpart to arteries; the aging disease of this tissue is chronic-venous-disease (varicose veins / CVI).

Wall structure

Like arteries, veins have three layers, but the proportions differ sharply:

LayerVeinContrast with artery
Tunica intimaEndothelium + thin subendothelial layer; folds form the valve cuspsSimilar endothelium; valves are venous-specific
Tunica mediaThin; sparse [[vsmcsmooth muscle]] + collagen, relatively little elastin
Tunica adventitiaOften the thickest layer; collagen (types I and III), some longitudinal smooth muscleRelatively thinner in arteries

The relatively elastin-poor, collagen-dominated, thin-media wall makes veins compliant capacitance reservoirs but also means wall integrity depends heavily on ECM balance — which is where venous aging strikes (below).12

Venous valves and the calf muscle pump

Lower-limb venous return against gravity depends on two coupled systems:

  1. Bicuspid venous valves — more numerous distally in the leg, they prevent retrograde (refluxing) flow. Valve competence is the single most important determinant of ambulatory venous pressure.
  2. The calf muscle pump (skeletal-muscle) — contraction of the calf during walking compresses the deep veins and propels blood upward; combined with competent valves, this drops foot venous pressure from the standing hydrostatic column (~90 mmHg) toward ~30 mmHg during ambulation.

Failure of either — valve incompetence or an inadequate pump — raises ambulatory venous pressure, the hemodynamic driver of chronic-venous-disease.12

Aging of the venous wall

Venous aging is the low-pressure, valve-centric analogue of arterial-stiffening:

  • ECM remodeling / MMP imbalance. Elevated venous hydrostatic pressure, hypoxia, and inflammation upregulate matrix metalloproteinases (mmp-1, mmp-2, mmp-3, MMP-7; MMP-9 enriched in endothelial cells and medial VSMCs) that degrade collagen and elastin, shifting the balance with their inhibitors (timp-1) toward net proteolysis. This weakens the wall (→ dilation) and, via BKCa-channel-mediated smooth-muscle hyperpolarization (blocked by iberiotoxin), promotes smooth-muscle relaxation/dilation directly.34
  • Valve degeneration. Valves become incompetent with age, especially in the superficial system; population data show superficial-vein reflux rising markedly with age while deep-system reflux does not.5
  • Endothelial dysfunction + inflammation. Venous hypertension drives leukocyte–endothelial adhesion and glycocalyx disruption, a chronic inflammatory wall state, with plausible contribution from endothelial/fibroblast cellular-senescence and sasp-associated ECM turnover (altered-intercellular-communication).12
  • Stretch/hypoxia mechanotransduction. Sustained wall stretch upregulates HIFs and reduces contractility, linking distension to a pro-remodeling hypoxic state.6

Venous valve microanatomy and development

Venous valves are bicuspid “pocket” (parietal) valves: two endothelium-covered leaflets seated in a slightly dilated segment of wall, the valve sinus, with a thickened wall ridge (the agger) at the leaflet attachment. They occur down to tributaries as small as ~0.1 mm.7 Their distribution is distal-predominant and proximally sparse: the inferior vena cava is valveless in essentially all individuals, the common iliac carries valves in only ~1–7% and the external iliac ~22–33%, rising to ~67–93% near the saphenofemoral junction and becoming dense in the calf and distal veins.8 This gradient matters — the proximal valveless segments place the entire orthostatic pressure column on the first competent valve downstream.

The valve sinus pocket is a low-shear, hypoxic microenvironment behind the leaflet. This is functionally double-edged: it is where the leaflet’s anticoagulant endothelial program is most needed, and it is the anatomical nidus where deep-vein thrombi initiate (valvular stasis + local hypoxia drive thrombosis).910

Valve endothelial specialization + the developmental program. The endothelium lining the valve is not generic luminal endothelium: hemodynamic forces (oscillatory/low shear in the sinus) induce a distinct, antithrombotic perivalvular endothelial gene program (high THBD/thrombomodulin, EPCR, and TFPI; low vWF), and disrupting it promotes DVT.11 Valve morphogenesis runs on a program shared with lymphatic valves: mechano-sensing activates the transcription factors PROX1 and FOXC2, which cooperate to control connexin-37 (GJA4) and calcineurin/NFATc1 signaling.12 In Cx37-null mice, lymphatic valves are absent and the few mature venous valves that do form are severely reduced;13 integrin-α9/fibronectin-EIIIA matrix assembly14 and Notch15 are also required. Crucially, this program overlaps with cardiac valve development — NFATc1,16 BMP2,17 Notch, Wnt, periostin, and endothelial-to-mesenchymal transition (EndMT) are shared between the two valve beds. The leaflet’s internal ECM stratification (dual endothelial layers over a collagen–elastin core with a proteoglycan-rich middle) is well-documented for cardiac valves but largely extrapolated to venous valves rather than directly characterized. no-mechanism

Venous valve failure — cellular mechanisms

Incompetence arises by two distinct routes that the literature is careful to separate:1819

  1. Primary valvular incompetence — the leaflet itself stretches, elongates, thins, or (rarely) is congenitally absent; commissures widen. Human EPHB4 loss-of-function causes venous valve aplasia/agenesis,20 and FOXC2 mutations (lymphedema-distichiasis syndrome) cause primary lower-limb venous valve failure21 — direct genetic proof that the developmental program governs adult valve competence.
  2. Annular (wall) dilation — the vein wall dilates at the valve station until the two cusps can no longer coapt, producing reflux through structurally intact leaflets. This couples valve failure directly to the vein-wall ECM/MMP remodeling above.
  3. Secondary (post-thrombotic) destruction — a prior DVT scars and tethers the leaflets; this is the most damaging form and the reason prior DVT is the strongest progression risk factor.

Across all three, the valve sinus inflammatory cascade is central: the low-shear pocket traps leukocytes; experimental venous hypertension drives monocyte/macrophage infiltration of the leaflets with progressive remodeling,22 and MMP-mediated leaflet ECM degradation23 weakens the cusp. There is growing evidence that EndMT is reactivated in varicose veins under altered flow24 — a striking echo of the EndMT that built the valve in development and that drives cardiac valve disease. Whether venous valve number declines with chronological age is widely repeated but not cleanly established in the primary literature. unsourced

Comparison to cardiac (heart) valves

The two valve systems share a developmental origin and several failure mechanisms, but diverge sharply in structure and dominant pathology:

FeatureVenous valveCardiac valve (heart)
GeometryBicuspid pocket valve in a sinusSemilunar (aortic/pulmonary, 3 cusps) or atrioventricular (mitral 2 / tricuspid 3)
Pressure loadLow (gravity/hydrostatic column)High (systemic/pulmonary arterial pressure)
Leaflet cell populationsSpecialized valve endothelium; a resident interstitial-cell population is not well characterized no-mechanismValve endothelial cells (VECs) + a defined valve interstitial cell (VIC) population
ECM organizationCollagen–elastin core + proteoglycan (largely extrapolated)Trilaminar: fibrosa (collagen) / spongiosa (proteoglycan) / ventricularis-atrialis (elastin)
Shared developmentPROX1, FOXC2, NFATc1/calcineurin, connexins, EndMTNFATc1, Notch1, BMP, Wnt, periostin, EndMT
Dominant aging failureReflux (leaflet stretch + wall dilation) ± post-thrombotic scarringCalcific stenosis (osteogenic VIC) or myxomatous prolapse (proteoglycan accumulation)
CalcificationNot a featureProminent (esp. aortic)

What’s shared: MMP/ADAMTS-driven ECM degradation, proteoglycan/versican remodeling, mechanical-stress-driven cell activation, and EndMT reactivation appear in both. Myxomatous mitral valve degeneration (mitral valve prolapse) is driven by proteoglycan accumulation, VIC activation, and ADAMTS5/versican turnover25 — conceptually parallel to venous-wall ECM proteolysis. What differs: osteogenic calcification (VIC → osteoblast transdifferentiation via RUNX2/BMP, repressed by NOTCH1)2627 and a defined VIC population are hallmarks of cardiac valves with no clear venous analogue.

The genetic bridge. This is the most striking correlation: the varicose-veins GWAS identifies 30 independent loci, several of which implicate machinery central to cardiac valve and connective-tissue biology — PPP3R1 (calcineurin B regulatory subunit, i.e. the NFATc1/calcineurin valve-development axis), PIEZO1 (a mechanosensor near the 16q24 locus), and CASZ1 (strongest association; a cardiac-development/blood-pressure locus on chr1) are confirmed GWAS hits. FBN2 (fibrillin-2, the Marfan-spectrum connective-tissue machinery) appears in eQTL analysis of the PIEZO1-region lead SNP rs2911463 as a regulated downstream gene — it is an eQTL association, not itself an independent GWAS locus.28 Connective-tissue disorders hit both beds — FBN1 (fibrillin-1) mutations in Marfan predict mitral valve prolapse,29 while FOXC2 governs venous valves. And remarkably, PROX1 — the canonical venous/lymphatic valve transcription factor — also protects against myxomatous heart-valve degeneration by restraining PDGF-B,30 a direct molecular thread tying the two valve systems together. A clinical co-occurrence of varicose veins and mitral valve prolapse is mechanistically plausible from this shared connective-tissue/calcineurin biology but is not cleanly established epidemiologically. needs-replication

For the engineering counterpart — can these valves be repaired or replaced? — see venous-valve-reconstruction.

Clinically important veins (lower limb)

  • Superficial system: great saphenous vein (GSV) and small saphenous vein (SSV) — the usual site of truncal reflux and the targets of endovenous ablation in chronic-venous-disease.
  • Deep system: femoral, popliteal, tibial veins — deep reflux is more often post-thrombotic and less age-driven.
  • Perforators: connect superficial → deep; incompetent perforators contribute to recurrent disease.

Footnotes

Footnotes

  1. doi:10.1056/NEJMra055289 · Bergan JJ et al. · N Engl J Med 2006;355(5):488–498 · review (landmark) · PMID 16885552 · venous wall structure, valve function, reflux/venous-hypertension mechanism ↩ ↩2 ↩3

  2. doi:10.1161/CIRCULATIONAHA.113.006898 · Eberhardt RT, Raffetto JD · Circulation 2014;130(4):333–346 · review · PMID 25047584 · venous hemodynamics, calf-pump physiology, CVI mechanism ↩ ↩2 ↩3

  3. doi:10.20517/2574-1209.2021.16 · Raffetto JD, Khalil RA · Vessel Plus 2021;5:36 · review (mechanistic) · PMID 34250453 · MMP-1, -2, -3, -7 elevated in VVs (MMP-2 activity specifically increased); MMP/TIMP ECM remodeling of vein wall; collagen+elastin degradation; dilation via BKCa-channel-mediated SMC hyperpolarization ↩

  4. doi:10.2174/157016108784911957 · Raffetto JD, Khalil RA · Curr Vasc Pharmacol 2008;6(3):158–172 · review · PMID 18673156 · MMP-driven venous dilation + valve dysfunction ↩

  5. doi:10.1016/j.jvs.2008.04.029 · Maurins U et al. (Bonn Vein Study) · J Vasc Surg 2008;48(3):680–687 · observational, population-based · enrolled n=3072, analysis n=3016, ages 18–79 · superficial-vein reflux 21.0% (95% CI 19.5–22.5); deep-vein reflux 20.0% (95% CI 18.6–21.5); overall reflux (>500 ms) 35.3%; superficial reflux rises markedly with age, deep shows no clear age trend · PMID 18586443 ↩

  6. doi:10.1016/j.jvs.2010.09.018 · Lim CS et al. · J Vasc Surg 2011;53(3):764–773 · in-vivo (rat IVC) · stretch → HIF upregulation + reduced contraction · PMID 21106323 ↩

  7. doi:10.1002/ca.10141 · Phillips MN et al. · Clin Anat 2004;17(1):55–60 · anatomical · PMID 14695589 · bicuspid parietal micro-valves with sinus pockets in superficial lower-limb veins, down to ~0.1 mm tributaries ↩

  8. doi:10.1002/ar.1092170413 · Banjo AO · Anat Rec 1987;217(4):407–412 · comparative anatomy · PMID 3592268 · valves absent in IVC in all subjects; common iliac 1–7%, external iliac 22–33%, femoral near-SFJ 67–93% — distal-predominant gradient ↩

  9. doi:10.1146/annurev-physiol-012110-142305 · Bovill EG, van der Vliet A · Annu Rev Physiol 2011;73:527–545 · review · PMID 21034220 · low-shear valve-sinus pocket is hypoxic; valvular-stasis hypoxia links to thrombosis initiation ↩

  10. doi:10.1172/JCI60229 · Mackman N · J Clin Invest 2012;122(7):2331–2336 · review · PMID 22751108 · venous thrombi initiate in valve-sinus pockets (stasis + low O₂) ↩

  11. doi:10.1172/JCI124791 · Welsh JD et al. · J Clin Invest 2019;129(12):5489–5500 · in-vivo (mouse + human saphenous vein) · PMID 31710307 · oscillatory/low shear drives a distinct antithrombotic perivalvular endothelial gene program (THBD/thrombomodulin high, EPCR high, TFPI high, vWF low, P-selectin surface-low, ICAM1 low); FOXC2 and PROX1 are specifically expressed in this perivalvular endothelium; conditional Foxc2 deletion in perivalvular endothelium abrogates the antithrombotic phenotype and promotes DVT ↩

  12. doi:10.1016/j.devcel.2011.12.020 · Sabine A et al. · Dev Cell 2012;22(2):430–445 · in-vivo (mouse) · PMID 22306086 · keystone lymphatic-valve study: flow-sensing → PROX1 + FOXC2 cooperate to control connexin-37 and calcineurin/NFATc1 in lymphatic-valve formation; the program is shared with venous valves (paper explicitly studies lymphatic vessels; extrapolation to venous valves supported by the overlap in TF expression and the Welsh 2019 in-vivo venous data) ↩

  13. doi:10.1016/j.ydbio.2012.10.032 · Munger SJ et al. · Dev Biol 2013;373(2):338–348 · in-vivo (mouse KO) · PMID 23142761 · connexin-37 (GJA4)-null mice have profoundly impaired lymphatic valve formation and severely reduced mature venous valves (shared Cx37-dependence across valve beds) ↩

  14. doi:10.1016/j.devcel.2009.06.017 · Bazigou E et al. · Dev Cell 2009;17(2):175–186 · in-vivo (mouse) · PMID 19686679 · integrin-α9 / fibronectin-EIIIA matrix assembly required for valve morphogenesis ↩

  15. doi:10.1242/dev.101188 · Murtomaki A et al. · Development 2014;141(12):2446–2451 · in-vivo (mouse) · PMID 24917500 · Notch signaling in lymphatic valve formation (shared with cardiac Notch role) ↩

  16. doi:10.1016/j.ydbio.2006.01.017 · Lange AW, Yutzey KE · Dev Biol 2006;292(2):407–417 · in-vivo (mouse) · PMID 16680826 · NFATc1 in developing heart-valve endocardium (RANKL-responsive) — shared NFATc1/calcineurin axis with venous/lymphatic valves ↩

  17. doi:10.1016/j.ydbio.2017.08.008 · Saxon JG et al. · Dev Biol 2017;430(1):113–128 · in-vivo (mouse) · PMID 28790014 · endocardial-lineage BMP2 required for AV cushion maturation (BMP arm of cardiac valve EndMT) ↩

  18. doi:10.1258/phleb.2007.007027 · Raffetto JD, Khalil RA · Phlebology 2008;23(2):85–98 · review · PMID 18453484 · distinguishes primary valve incompetence from annular (wall) dilation causing loss of cusp coaptation ↩

  19. doi:10.1016/j.jvs.2007.09.028 · Bergan JJ et al. · J Vasc Surg 2008;47(1):183–192 · review (animal models) · PMID 18178472 · venous hypertension → leukocyte trapping, inflammation, valve + wall remodeling ↩

  20. doi:10.1172/jci.insight.140952 · Lyons OTA et al. · JCI Insight 2021;6(14):e140952 · human genetics · PMID 34403370 · EPHB4 loss-of-function causes venous valve aplasia/agenesis ↩

  21. doi:10.1161/CIRCULATIONAHA.106.675348 · Mellor RH et al. · Circulation 2007;115(14):1912–1920 · human · PMID 17372167 · FOXC2 mutations associated with primary lower-limb venous valve failure (lymphedema-distichiasis) ↩

  22. doi:10.1016/j.jvs.2004.02.044 · Takase S et al. · J Vasc Surg 2004;39(5):1060–1066 · in-vivo (animal) · PMID 15192576 · experimental venous hypertension → monocyte/macrophage infiltration of valve leaflets + progressive remodeling ↩

  23. doi:10.1016/bs.pmbts.2017.02.003 · Chen Y, Peng W, Raffetto JD, Khalil RA · Prog Mol Biol Transl Sci 2017;147:267–299 · review · PMID 28413031 · MMP-mediated ECM degradation in vein wall + valve remodeling ↩

  24. doi:10.1007/s00018-025-05854-y · Ahalya S et al. · Cell Mol Life Sci 2025;82(1) · review/mechanistic · PMID 41055734 · altered venous flow drives EndMT in varicose veins (venous-side EndMT parallel to cardiac valve EndMT) needs-replication ↩

  25. doi:10.1016/j.athoracsur.2017.11.035 · Absi TS et al. · Ann Thorac Surg 2018;105(5):1486–1494 · human molecular · PMID 29248417 · altered ADAMTS5 → versican proteoglycan turnover in Barlow myxomatous mitral valve ↩

  26. doi:10.1161/01.CIR.0000070591.21548.69 · Rajamannan NM et al. · Circulation 2003;107(17):2181–2184 · human histology · PMID 12719282 · calcified aortic valves express osteoblast markers (Cbfa1/RUNX2, osteopontin) — osteogenic VIC transdifferentiation ↩

  27. doi:10.1038/nature03940 · Garg V et al. · Nature 2005;437(7056):270–274 · human genetics · PMID 16025100 · NOTCH1 loss-of-function → bicuspid aortic valve + accelerated calcification (Notch represses RUNX2) ↩

  28. doi:10.1161/CIRCULATIONAHA.118.035584 · Fukaya E et al. · Circulation 2018;138(25):2869–2880 · GWAS (UK Biobank, 337,536 individuals; 9,577 cases) · PMID 30566020 · PMC6400474 · 30 independent genome-wide significant loci; strongest hit CASZ1 (rs11121615; P=3.71×10⁻⁶⁵); other notable hits: PPP3R1 (calcineurin B regulatory subunit; eQTL for PPP3R1/WDR92/PLEK) and PIEZO1 (rs2911463; P=4.81×10⁻²⁹); FBN2 is an eQTL gene near the PIEZO1/GALNS locus (rs2911463 eQTL associations include GALNS and FBN2) — not itself an independent GWAS locus; height causally associated with varicose veins by MR (IVW OR 1.26; P=2.07×10⁻¹⁶) ↩

  29. doi:10.1016/j.ijcard.2012.10.044 · Kühne K et al. · Int J Cardiol 2013;168(2):1622–1623 · human · PMID 23176764 · FBN1 mutation characteristics predict mitral valve prolapse in Marfan syndrome ↩

  30. doi:10.1161/CIRCRESAHA.123.323027 · Ho YC et al. · Circ Res 2023;133(5):463–480 · in-vivo (mouse) · PMID 37555328 · PROX1 (venous/lymphatic valve TF) inhibits PDGF-B to prevent myxomatous heart-valve degeneration — direct cross-bed molecular link ↩

Graph View

Backlinks